查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2019269

全球鼻腔給藥裝置市場：依藥物類型、裝置類型、最終用戶、應用及地區分類－市場規模、市場動態、機會分析及2026-2035年預測

Global Nasal Mucosa Drug Supply Device Market: By Drug Type, Device Type, End-User, Application, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

鼻腔給藥裝置市場正經歷快速擴張，反映出人們對非侵入性高效給藥方式日益成長的需求。預計2025年市場規模將達到93.6億美元，未來十年將成長近一倍，2035年達到約202.1億美元。這一顯著成長意味著8.0%的強勁複合年成長率，凸顯了鼻腔給藥技術在各個醫療領域日益普及和廣泛接受。

推動該市場快速成長的主要因素之一是對快速、無針全身給藥方式的需求日益成長。患者和醫護人員都在尋求傳統注射和口服藥物的替代方案，他們更傾向於使用起效更快、患者舒適度更高的鼻腔給藥裝置。對於那些害怕針頭或需要快速起效的患者（例如在緊急情況下），這種轉變尤其重要。

顯著的市場趨勢

鼻腔給藥裝置市場呈現典型的寡占格局，少數主要企業主導市場，合計控制約70%的OEM（目的地設備製造商）產量。引領這一競爭格局的是AptarGroup、Nemera、Becton Dickinson (BD) 和Teleflex，它們各自憑藉著無可比擬的規模、強大的知識產權組合和深厚的監管專業知識，維持著穩固的市場地位。

AptarGroup是該領域銷量領先的公司，擁有超過100項與多劑量和單劑量給藥系統相關的專利。其技術是其暢銷急救吸入器的核心，該產品年銷售額超過2億美元。同時，Nemera專注於無防腐劑幫浦系統，開闢了一個利潤豐厚的細分市場。該公司對嚴格遵守良好生產規範 (GMP) 和精確劑量控制的承諾，使其在歐洲市場佔據了25%的領先佔有率。

貝克頓·迪金森公司 (BD) 正利用其 Accuspray 平台支持大規模疫苗接種活動，鑑於全球對免疫計劃的重視，這是一個至關重要的成長領域。 BD 從中受益匪淺，其獲得 FDA核准的複合食品藥物管理局相關合約的特許權使用費約為 1 億美元。

關鍵成長要素

居家照護和自我給藥方式的轉變是鼻粘膜給藥裝置市場成長的關鍵促進因素。自新冠疫情爆發以來，宏觀經濟領域出現了一系列旨在減輕醫院和臨床機構負擔的措施。這項轉變源自於減輕醫院負擔、最佳化資源配置並最終降低醫療成本的需求。患者和醫療服務提供者都越來越傾向於採用能夠在傳統臨床環境之外進行有效治療的解決方案。

新機會的趨勢

乾粉製劑的創新在推動鼻腔給藥裝置在市場上的廣泛應用方面發揮了至關重要的作用。這些先進的給藥系統徹底改變了鼻內給藥方式，為傳統的液體噴霧劑提供了更高效的替代方案。透過使用冷凍乾燥粉末，這些裝置能夠以乾燥形式精準穩定地輸送藥物，從而延長熱敏性藥物的保存期限並提高其穩定性。

最佳化障礙

製劑方面的限制是鼻黏膜給藥裝置市場成長面臨的一大挑戰。其中一個主要障礙是難以有效地將胜肽類和蛋白質等高分子量化合物經由鼻腔遞送。這些大分子藥物通常面臨吸收和生物利用度方面的障礙，難以在標靶達到治療濃度。這種限制縮小了可用於鼻腔給藥的藥物範圍，進而限制了某些先進治療方法的市場潛力。

目錄

第1章執行摘要：全球鼻腔給藥裝置市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 按地區分類的主要調查受訪者組成
  • 本研究的前提
  • 市場規模估算
  • 數據檢驗

第3章：全球鼻粘膜給藥裝置市場概述

  • 產業價值鏈分析
    • 原物料供應商
    • 設備製造商
    • 分銷管道
    • 最終用戶
  • 產業展望
    • 鼻腔給藥技術進展
    • 監理形勢與核准框架
    • 產品核准及研發管線分析
    • 世界貿易分析
    • 主要買家和供應商
  • PESTLE分析
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場成長及前景
    • 市場收入估算與預測（2020-2035 年）
    • 2020-2035年市場規模估算與預測（單位：百萬）
    • 價格趨勢分析

第4章：鼻粘膜給藥裝置的全球市場分析

  • 競爭格局概述
    • 市場集中度
    • 企業市場占有率分析（以金額為準，%），2025 年
    • 競爭對手分析與基準測試

第5章：鼻粘膜給藥裝置的全球市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測（2020-2035）
    • 依藥物類型
      • 主要分析結果
        • 呼吸系統藥物
        • 止痛藥
        • 疫苗
        • 神經系統藥物
        • 荷爾蒙療法藥物
        • 急救
    • 透過使用
      • 主要分析結果
        • 過敏性鼻炎
        • 鼻竇炎和鼻塞
        • 偏頭痛
        • 其他
    • 最終用戶
      • 主要分析結果
        • 醫院和診所
        • 居家醫療
        • 藥局
        • 其他
    • 按地區
      • 主要分析結果
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英格蘭
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 韓國
          • 澳洲和紐西蘭
          • ASEAN
            • 印尼
            • 馬來西亞
            • 泰國
            • 新加坡
            • 其他東協國家
          • 其他亞太地區
        • 中東和非洲
          • 阿拉伯聯合大公國
          • 沙烏地阿拉伯
          • 南非
          • 其他中東和非洲地區
        • 南美洲
          • 阿根廷
          • 巴西
          • 南美洲其他地區

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太地區市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

  • AptarGroup
  • Becton Dickinson and Company
  • GlaxoSmithKline
  • Johnson &Johnson
  • Merck &Co.
  • Novartis
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries
  • Other Prominent Players

第12章附錄

簡介目錄
Product Code: AA03261725

The nasal mucosa drug supply device market is experiencing rapid expansion, reflecting a growing preference for non-invasive and efficient drug delivery methods. Starting from an estimated baseline value of USD 9.36 billion in 2025, the market is projected to nearly double over the next decade, reaching approximately USD 20.21 billion by 2035. This impressive growth represents a robust compound annual growth rate (CAGR) of 8.0%, underscoring the increasing adoption and acceptance of nasal drug delivery technologies across various healthcare sectors.

One of the primary drivers behind this market surge is the rising demand for systemic drug delivery methods that are both rapid and needle-free. Patients and healthcare providers alike are seeking alternatives to traditional injections and oral medications, favoring nasal devices that offer faster onset of action and improved patient comfort. This shift is particularly important for individuals with needle phobia or those requiring quick therapeutic effects, such as in emergency situations.

Noteworthy Market Developments

The nasal mucosa drug supply device market operates as a classic oligopoly, dominated by a small group of key players that collectively control about 70% of original equipment manufacturer (OEM) production. Leading this competitive landscape are AptarGroup, Nemera, Becton Dickinson (BD), and Teleflex, each leveraging their unmatched scale, robust intellectual property portfolios, and deep regulatory expertise to maintain its powerful market positions.

AptarGroup stands out as the revenue leader in this sector, boasting over 100 patents related to both multi-dose and unit-dose delivery systems. Their technologies are integral to blockbuster rescue inhalers, generating more than $200 million in annual sales. Nemera, meanwhile, has carved out high-margin niches by focusing on preservative-free pump systems. Their commitment to good manufacturing practice (GMP) excellence and precision dosing has earned them a commanding 25% share of the European market.

Becton Dickinson (BD) leverages its Accuspray platforms to support large-scale vaccine deployments, a critical area of growth given the global emphasis on immunization programs. BD benefits from substantial royalty income, generating around $100 million from combination-device agreements following approvals by the U.S. Food and Drug Administration (FDA).

Core Growth Drivers

The shift towards at-home care and self-administration has become a significant driver of growth in the nasal mucosa drug supply device market. Since the COVID-19 pandemic, there has been a broad macroeconomic movement aimed at reducing the strain on hospitals and clinical settings. This shift is motivated by the need to alleviate hospital burdens, optimize resource allocation, and ultimately reduce healthcare costs. Patients and healthcare providers alike are increasingly embracing solutions that enable effective treatment outside traditional clinical environments.

Emerging Opportunity Trends

Innovations in dry-powder devices are playing a crucial role in driving the adoption of nasal mucosa drug supply devices within the market. These advanced delivery systems have transformed the way medications are administered nasally by offering a sophisticated alternative to traditional liquid sprays. By utilizing lyophilized powders, these devices enable the precise and stable delivery of drugs in a dry form, which can enhance the shelf life and stability of sensitive pharmaceutical compounds.

Barriers to Optimization

Formulation limitations present a significant challenge that could hamper the growth of the nasal mucosa drug supply device market. One of the primary obstacles lies in the difficulty of effectively delivering high molecular weight compounds, such as peptides and proteins, through the nasal route. These large molecules often face barriers related to absorption and bioavailability, making it challenging to achieve therapeutic concentrations in the target area. This limitation restricts the range of drugs that can be formulated for nasal delivery, thereby narrowing the market potential for certain advanced therapies.

Detailed Market Segmentation

By device type, metered-dose spray systems (MDSS) held a dominant position in the nasal mucosa drug supply device market, accounting for 44.85% of the global revenue in 2025. This leadership is largely attributed to the unparalleled precision these systems offer in delivering exact doses of medication, which is essential for both patient safety and therapeutic efficacy. The ability of MDSS to consistently administer controlled amounts of drugs makes them highly favored by pharmaceutical engineers who prioritize accuracy in drug formulation and delivery.

By application, allergic rhinitis accounts for a significant portion of the market revenue, capturing approximately 41.18%. This impressive share is driven by the large epidemiological prevalence of the condition as well as the pharmacokinetic advantages offered by treatments targeting it. Allergic rhinitis forms the volume backbone of the market, even though central nervous system (CNS) devices tend to generate higher profit margins. The widespread occurrence of allergic rhinitis ensures consistent demand, making it a critical focus area within nasal drug delivery applications.

By end users, hospitals and clinics dominate the nasal mucosa drug supply device market, holding a significant 56% share. This strong position is maintained through the securing of high-value contracts, reflecting the critical role these healthcare facilities play despite an increasing trend toward home-care solutions. The preference for hospitals and clinics is largely due to the irreplaceable nature of acute and supervised medical treatments that require precise and immediate drug delivery.

Segment Breakdown

By Device Type

  • Metered-Dose Spray Systems
  • Breath-Actuated Systems
  • Multi-Dose Dispensers
  • Nebulizers & Atomizers
  • Powder-Based Delivery Systems
  • Others

By Drug Type

  • Respiratory Drugs
  • Pain Management Drugs
  • Vaccines
  • Neurological Drugs
  • Hormone Therapies
  • Emergency Drugs

By Application

  • Allergic Rhinitis
  • Sinusitis & Nasal Congestion
  • Migraine
  • Others

By End-User

  • Hospitals & Clinics
  • Home Care
  • Retail Pharmacies
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America stands as the undisputed leader in the global market, commanding an estimated 45.8% share of the total market landscape. This dominant position is the result of several interrelated factors that have shaped the region's unique market dynamics and growth trajectory. Central to this leadership is the high adoption of biologics and drug-device combination products, which benefit from a healthcare system that supports premium pricing models. These pricing structures allow manufacturers to justify the often substantial research and development costs associated with innovative technologies such as novel mucosal atomizers.
  • Another significant driver of North America's market dominance is the ongoing opioid epidemic, a public health crisis that has necessitated widespread deployment of rescue therapeutics at the community level. In response to this tragic epidemic, millions of unit-dose intranasal naloxone devices-such as Narcan-are distributed annually across first responders, educational institutions, and private homes. This large-scale distribution has dramatically increased the regional market volume for intranasal delivery devices, creating a robust demand that far exceeds that of many other regions.
  • Furthermore, the presence of a mature regulatory infrastructure specifically designed to address the complexities of combination products has played a pivotal role in fostering domestic biopharmaceutical investment. This regulatory environment offers clear guidelines and pathways for approval, reducing uncertainty and facilitating faster development timelines for intranasal drug-device products.

Leading Market Participants

  • AptarGroup
  • Becton Dickinson and Company
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Nasal Mucosa Drug Supply Device Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Nasal Mucosa Drug Supply Device Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers
    • 3.1.2. Device Manufacturers
    • 3.1.3. Distribution Channels
    • 3.1.4. End Users
  • 3.2. Industry Outlook
    • 3.2.1. Technological Advancements in Nasal Drug Delivery
    • 3.2.2. Regulatory Landscape & Approval Framework
    • 3.2.3. Product Approvals & Pipeline Analysis
    • 3.2.4. Global Trade Analysis
    • 3.2.5. Key Buyers & Suppliers
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Market Volume Estimates and Forecast (Mn Units), 2020-2035
    • 3.5.3. Price Trend Analysis

Chapter 4. Global Nasal Mucosa Drug Supply Device Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Nasal Mucosa Drug Supply Device Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 5.2.1. By Drug Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Respiratory Drugs
        • 5.2.1.1.2. Pain Management Drugs
        • 5.2.1.1.3. Vaccines
        • 5.2.1.1.4. Neurological Drugs
        • 5.2.1.1.5. Hormone Therapies
        • 5.2.1.1.6. Emergency Drugs
    • 5.2.2. By Application
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Allergic Rhinitis
        • 5.2.2.1.2. Sinusitis & Nasal Congestion
        • 5.2.2.1.3. Migraine
        • 5.2.2.1.4. Others
    • 5.2.3. By End-User
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Hospitals & Clinics
        • 5.2.3.1.2. Home Care
        • 5.2.3.1.3. Retail Pharmacies
        • 5.2.3.1.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. North America
          • 5.2.4.1.1.1. The U.S.
          • 5.2.4.1.1.2. Canada
          • 5.2.4.1.1.3. Mexico
        • 5.2.4.1.2. Europe
          • 5.2.4.1.2.1. Western Europe
            • 5.2.4.1.2.1.1. The UK
            • 5.2.4.1.2.1.2. Germany
            • 5.2.4.1.2.1.3. France
            • 5.2.4.1.2.1.4. Italy
            • 5.2.4.1.2.1.5. Spain
            • 5.2.4.1.2.1.6. Rest of Western Europe
          • 5.2.4.1.2.2. Eastern Europe
            • 5.2.4.1.2.2.1. Poland
            • 5.2.4.1.2.2.2. Russia
            • 5.2.4.1.2.2.3. Rest of Eastern Europe
        • 5.2.4.1.3. Asia Pacific
          • 5.2.4.1.3.1. China
          • 5.2.4.1.3.2. India
          • 5.2.4.1.3.3. Japan
          • 5.2.4.1.3.4. South Korea
          • 5.2.4.1.3.5. Australia & New Zealand
          • 5.2.4.1.3.6. ASEAN
            • 5.2.4.1.3.6.1. Indonesia
            • 5.2.4.1.3.6.2. Malaysia
            • 5.2.4.1.3.6.3. Thailand
            • 5.2.4.1.3.6.4. Singapore
            • 5.2.4.1.3.6.5. Rest of ASEAN
          • 5.2.4.1.3.7. Rest of Asia Pacific
        • 5.2.4.1.4. Middle East & Africa
          • 5.2.4.1.4.1. UAE
          • 5.2.4.1.4.2. Saudi Arabia
          • 5.2.4.1.4.3. South Africa
          • 5.2.4.1.4.4. Rest of MEA
        • 5.2.4.1.5. South America
          • 5.2.4.1.5.1. Argentina
          • 5.2.4.1.5.2. Brazil
          • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Drug Type
      • 6.2.1.2. By Application
      • 6.2.1.3. By End-User
      • 6.2.1.4. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Drug Type
      • 7.2.1.2. By Application
      • 7.2.1.3. By End-User
      • 7.2.1.4. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Drug Type
      • 8.2.1.2. By Application
      • 8.2.1.3. By End-User
      • 8.2.1.4. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Drug Type
      • 9.2.1.2. By Application
      • 9.2.1.3. By End-User
      • 9.2.1.4. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Drug Type
      • 10.2.1.2. By Application
      • 10.2.1.3. By End-User
      • 10.2.1.4. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. AptarGroup
  • 11.2. Becton Dickinson and Company
  • 11.3. GlaxoSmithKline
  • 11.4. Johnson & Johnson
  • 11.5. Merck & Co.
  • 11.6. Novartis
  • 11.7. Pfizer
  • 11.8. Sanofi
  • 11.9. Teva Pharmaceutical Industries
  • 11.10. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators